Literature DB >> 19207323

Prospective multicenter study for evaluation of safety, efficacy, and esthetic results of cross-linked polyacrylamide hydrogel in 81 patients.

Marianne Wolters1, Hermann Lampe.   

Abstract

BACKGROUND: Cross-linked polyacrylamide hydrogel, a nonabsorbable soft-tissue filler, has given promising results regarding efficacy and safety at 24 months of follow-up, but because adverse reactions have been described years after injection of some other fillers, a prolonged follow-up was required.
OBJECTIVE: To examine the safety and efficacy of the hydrogel in facial contouring after 36 to 48 months (mean 40 months).
METHODS: In this prospective multicenter trial, the esthetic results and safety of the treatments were assessed at 36 to 48 months, and the results were compared with those seen previously.
RESULTS: Eighty-one patients participated. The investigator rated esthetic results as very good or good in 99% of cases, and 98% of patients rated esthetic results as very satisfactory or satisfactory. Two of nine reported adverse events were possibly related to hydrogel treatment. One was initial infection after a touch-up, and one was continuous itching 1 year after injection.
CONCLUSION: The polyacrylamide hydrogel filler was still well tolerated after 36 to 48 months with no long-term unexpected adverse events and no loss of filler effect.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19207323     DOI: 10.1111/j.1524-4725.2008.01040.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  2 in total

Review 1.  Emerging permanent filler technologies: focus on Aquamid.

Authors:  Paul S Yamauchi
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-10-10

2.  Clinicopathological Analysis of 90 Cases of Polyacrylamide Hydrogel Injection for Breast Augmentation Including 2 Cases Followed by Breast Cancer.

Authors:  Ying Yang; Shumo Li; Jia He; Xian Zhao; Wei Chen; Xiaoming Dai; Liu Liu
Journal:  Breast Care (Basel)       Date:  2019-05-29       Impact factor: 2.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.